3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Tumor Lysis Syndrome
2
Lymphoma
1
Leukemia
1
Inflammation
1
Hyperuricemia
1
Hematologic Neoplasms
1
Gout
1
Cardiovascular Diseases
1
Arthritis
1
Interventions
Rituximab
173
Cyclophosphamide
156
Vincristine
72
fludarabine phosphate
71
Etoposide
68
Doxorubicin
68
Prednisone
66
Filgrastim
58
Methotrexate
52
Cytarabine
51
fludarabine
49
Melphalan
48
Busulfan
47
Tacrolimus
41
Whole-Body Irradiation
39
Mycophenolic Acid
39
Granulocyte Colony-Stimulating Factor
37
Antilymphocyte Serum
31
Peripheral Blood Stem Cell Transplantation
30
Radiotherapy
27
Lenalidomide
25
Dexamethasone
25
Carmustine
23
Stem Cell Transplantation
22
Cyclosporine
22
Bortezomib
22
Gemcitabine
20
Bendamustine Hydrochloride
20
ibritumomab tiuxetan
19
Alemtuzumab
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma
×
Febuxostat
×
Clear all
NCT01724528
2014-11-03
FLORENCE
Menarini Group
Phase 3
Completed
346 enrolled
16 charts